Therapix Biosciences Ltd (NASDAQ:TRPX) is expanding its cannabinoid -based clinical pipeline beyond neurological disorders to potentially treat obstructive sleep apnea (OSA), a chronic sleep disorder. The company is investigating the efficacy of THX-OSA01, an oral THC/PEA formulation, for the … Read More
The post Therapix Biosciences: 2 New Cannabinoid Programs appeared first on Dagga Magazine.